AstraZeneca’s experimental breast cancer pill, camizestrant, faces a delayed decision from the US Food and Drug Administration, which has extended its review period to scrutinize additional data.

This extension follows an April vote by a majority of the FDA’s advisory panel against the drug when used in combination with a CDK4/6 inhibitor. The panel’s concerns centered on the design of a crucial late-stage trial, rather than issues of safety or efficacy.

In response, the Anglo-Swedish pharmaceutical giant confirmed it has submitted further analyses requested by the FDA to bolster its new drug application. This submission includes data on longer-term efficacy outcomes, slated for presentation at a conference on June 2.

Susan Galbraith, a senior executive at AstraZeneca, stated, “We look forward to continuing the dialogue with the FDA in order to bring the benefits of camizestrant with this innovative treatment strategy to eligible patients in the US as quickly as possible.”

Camizestrant is specifically developed for patients battling a form of breast cancer characterized by tumors carrying a particular mutation. The news of the FDA delay comes shortly after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of the drug last week.